Veranex expands preclinical services with acquisition of T3 Labs
Veranex, a pioneering service platform in the medtech industry, has announced the acquisition of T3 Labs, a reputable preclinical laboratory based in Atlanta, Georgia. This strategic move marks a significant enhancement of Veranex’s preclinical footprint in North America, further deepening its therapeutic expertise and offering clients increased flexibility.
Founded in 1997 by Dr. Klaus Lubbe, T3 Labs has evolved into a leader in preclinical evaluation services, operating from a state-of-the-art 33,000-square-foot facility in Atlanta. The laboratory specializes in research across 12 therapeutic areas, making it a strategic asset for Veranex’s continued growth and service expansion.
Integration into Veranex’s Expanding Portfolio
Pat Donnelly, CEO of Veranex, expressed enthusiasm about integrating T3 Labs into their family, citing the acquisition as a key step in realizing Veranex’s mission to streamline the entire medtech development process. He highlighted the growing preclinical market, increasing regulatory requirements, and the need for effective collaboration as driving forces behind this acquisition.
Veranex Acquires T3 Labs, Bolstering Its North American Preclinical Footprint
T3 Labs, an anchor in Atlanta’s Science Square, a burgeoning life sciences hub, boasts strategic community relationships with renowned institutions like the CDC, Emory University, and Georgia Tech. The experienced staff at T3 Labs, led by Sherry Farrugia and Dr. Jeff White, have contributed to the FDA clearance of over 60 products in the past decade.
Enhanced Capabilities and Future Prospects
The acquisition by Veranex is expected to bolster the company’s capabilities in delivering high-quality preclinical services. T3 Labs’ expertise complements Veranex PCS France, enhancing the company’s global preclinical offerings. This move positions Veranex to play a more prominent role in advancing medtech research and innovation.
Sherry Farrugia, the leader of T3 Labs, emphasized the benefits of joining forces with Veranex, anticipating a significant impact on the healthcare industry and their clients. Dr. Jeff White also echoed these sentiments, highlighting the shared values and standards of service excellence between the two organizations.
Commitment to Innovation and Client Service
With this acquisition, Veranex reaffirms its commitment to advancing scientific discovery and innovation in the medtech sector. The integration process begins immediately, with a focus on leveraging the synergies between T3 Labs and Veranex to deliver more integrated and customized services to the medtech community.